文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

抑制 yes 相关蛋白下调人恶性胸膜间皮瘤中 PD-L1(CD274)的表达。

Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.

机构信息

Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.

Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.

出版信息

J Cell Mol Med. 2018 Jun;22(6):3139-3148. doi: 10.1111/jcmm.13593. Epub 2018 Mar 24.


DOI:10.1111/jcmm.13593
PMID:29575535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5980156/
Abstract

Although tumour PD-L1 (CD274) expression had been used as a predictive biomarker in checkpoint immunotherapy targeting the PD1/PD-L1 axis in various cancers, the regulation of PD-L1 (CD274) expression is unclear. Yes-associated protein (YAP), an important oncogenic protein in Hippo signalling pathway, reportedly promotes cancer development. We investigated whether inhibition of YAP down-regulates PD-L1 (CD274) in human malignant pleural mesothelioma (MPM). Western blotting showed that 2 human MPM cell lines (H2052 and 211H) had increased PD-L1 protein expression compared to H290, MS-1 and H28 cells. In H2052 and 211H cells, PD-L1 mRNA expression was significantly increased compared to other MPM cell lines; YAP knockdown by small interfering RNA decreased PD-L1 protein and mRNA expression. Forced overexpression of the YAP gene increased PD-L1 protein expression in H2452 cells. Chromatin immunoprecipitation (ChIP) assay showed the precipitation of PD-L1 enhancer region encompassing 2 putative YAP-TEAD-binding sites in H2052 cells. We found that, in human MPM tissue microarray samples, YAP and PD-L1 concurrently expressed in immunohistochemistry stain (n = 70, P < .05, chi-square). We conclude that PD-L1 is correlated with YAP expression, and inhibition of YAP down-regulates PD-L1 expression in human MPM. Further study of how YAP regulates PD-L1 in MPM is warranted.

摘要

尽管肿瘤 PD-L1(CD274)表达已被用作针对 PD1/PD-L1 轴的各种癌症的检查点免疫治疗的预测性生物标志物,但 PD-L1(CD274)表达的调控尚不清楚。Yes 相关蛋白(YAP)是 Hippo 信号通路中的一种重要致癌蛋白,据报道可促进癌症发展。我们研究了抑制 YAP 是否会下调人类恶性胸膜间皮瘤(MPM)中的 PD-L1(CD274)。Western blot 显示,与 H290、MS-1 和 H28 细胞相比,2 个人类 MPM 细胞系(H2052 和 211H)的 PD-L1 蛋白表达增加。与其他 MPM 细胞系相比,H2052 和 211H 细胞中的 PD-L1 mRNA 表达显著增加;用小干扰 RNA 敲低 YAP 可降低 PD-L1 蛋白和 mRNA 表达。强制过表达 YAP 基因可增加 H2452 细胞中 PD-L1 蛋白的表达。染色质免疫沉淀(ChIP)分析显示,在 H2052 细胞中,PD-L1 增强子区域包含 2 个潜在的 YAP-TEAD 结合位点被沉淀。我们发现,在人类 MPM 组织微阵列样本中,YAP 和 PD-L1 在免疫组化染色中同时表达(n=70,P<0.05,卡方)。我们得出结论,PD-L1 与 YAP 表达相关,抑制 YAP 可下调人类 MPM 中的 PD-L1 表达。进一步研究 YAP 如何调节 MPM 中的 PD-L1 是必要的。

相似文献

[1]
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.

J Cell Mol Med. 2018-3-24

[2]
Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.

J Cell Mol Med. 2020-1

[3]
Targeting YAP in malignant pleural mesothelioma.

J Cell Mol Med. 2017-5-4

[4]
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.

Biochem Biophys Res Commun. 2017-9-16

[5]
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

J Thorac Oncol. 2017-6-16

[6]
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.

J Thorac Oncol. 2016-1

[7]
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.

J Thorac Oncol. 2017-10-24

[8]
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

PLoS One. 2015-3-16

[9]
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

Hum Pathol. 2017-8-12

[10]
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.

Hum Pathol. 2016-6

引用本文的文献

[1]
Recent Advances in Combination Therapy of YAP Inhibitors with Physical Anti-Cancer Strategies.

Biomolecules. 2025-6-29

[2]
YAP as a therapeutic target to reverse trastuzumab resistance.

Gastric Cancer. 2025-6-20

[3]
Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.

Cancer Biol Ther. 2023-12-31

[4]
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer.

J Pers Med. 2023-8-24

[5]
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer.

Cell Death Dis. 2023-9-26

[6]
YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer.

Int J Mol Sci. 2023-8-6

[7]
Searching for Novel Biomarkers in Thymic Epithelial Tumors: Immunohistochemical Evaluation of Hippo Pathway Components in a Cohort of Thymic Epithelial Tumors.

Biomedicines. 2023-7-1

[8]
Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC).

Cells. 2023-3-10

[9]
The Hippo signaling pathway: from multiple signals to the hallmarks of cancers.

Acta Biochim Biophys Sin (Shanghai). 2023-3-20

[10]
Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growth.

Oncol Rep. 2023-2

本文引用的文献

[1]
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.

Cytokine Growth Factor Rev. 2017-7-12

[2]
Drug development against the hippo pathway in mesothelioma.

Transl Lung Cancer Res. 2017-6

[3]
Immunotherapy for malignant pleural mesothelioma: current status and future directions.

Transl Lung Cancer Res. 2017-6

[4]
Novel systemic therapy against malignant pleural mesothelioma.

Transl Lung Cancer Res. 2017-6

[5]
Biomarkers of response to PD-1/PD-L1 inhibition.

Crit Rev Oncol Hematol. 2017-8

[6]
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.

Oncogene. 2017-6-12

[7]
Targeting YAP in malignant pleural mesothelioma.

J Cell Mol Med. 2017-5-4

[8]
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).

Oncotarget. 2017-4-18

[9]
The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.

Oncotarget. 2017-4-4

[10]
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

Lancet Oncol. 2017-3-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索